However, whether HIF-1α promotes CXCL12 production by BM-derived SC of CLL patients, thus leading to CXCR4 activation and SC-induced drug-resistance in leukemic cells, is currently unknown. This evidence concerns the gene CXCR4 and B-cell chronic lymphocytic leukemia.